Exclusive - Pfizer, BioNTech halt US COVID vaccine study after recruitment struggles

By Bhanvi Satija LONDON, April 1 (Reuters) - Vaccine makers Pfizer and BioNTech halted a large U.S. trial of their updated COVID-19 vaccine in healthy adults aged 50 to 64, saying enrollment in the ...

Pfizer, Valneva Report Strong Efficacy Data From Lyme Vaccine Trial

Pharmaceutical giant Pfizer and French vaccine maker Valneva reported positive topline results from their phase three study ...
Wall Street Journal

Novavax Licenses Rights to Key Vaccine Component to Pfizer

Novavax, the Covid-19 vaccine maker, has licensed the rights for a vaccine-enhancing component to Pfizer. Pfizer agreed to pay $30 million upfront, and could pay up to $500 million more if development ...
RAPS

Recon: Pfizer’s maternal RSV vaccine headed to FDA after hitting study endpoints; J&J to acquire heart pump maker Abiomed for $16.6B

Recon: Pfizer’s maternal RSV vaccine headed to FDA after hitting study endpoints; J&J to acquire heart pump maker Abiomed for $16.6B Welcome to Regulatory Reconnaissance, your daily regulatory news ...
The Business Journals

Vaccine maker looks to raise half a billion dollars to attack an $8 billion market

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The company could go up against ...